Ara Khachaturian

Jun 12, 2024 | nature.com | Suzanne Schindler |Marc Suárez-Calvet |Ara Khachaturian |Michelle M. Mielke |Yan Hu |Soeren Mattke

AbstractAnti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the need for biomarker confirmation of amyloid pathology. Blood biomarker (BBM) tests for amyloid pathology are more acceptable, accessible and scalable than amyloid PET or cerebrospinal fluid (CSF) tests, but have highly variable levels of performance.